MindWalk Holdings (HYFT) Capital Expenditures (2023 - 2026)
MindWalk Holdings (HYFT) posted quarterly Capital Expenditures of $572662.2 for Q2 2026, down 34.23% year-over-year from $870680.8 in Q2 2025, and up 2663.66% quarter-over-quarter from -$22337.7 in Q1 2026.
MindWalk Holdings (HYFT) Capital Expenditures (2023 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Capital Expenditures for 4 consecutive years, with $572662.2 the latest figure, recorded in Q2 2026.
- In Q2 2026, Capital Expenditures fell 34.23% year-over-year to $572662.2; the TTM figure through Apr 2026 stood at $291744.1 (down 47.16% YoY), while the FY2026 annual figure was $290343.4, down 49.38% from the prior year.
- Capital Expenditures rose to $572662.2 in Q2 2026 per HYFT's latest filing, from -$22337.7 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.9 million in Q2 2023 and bottomed at -$220510.7 in Q4 2023.
- Historically, Capital Expenditures has averaged $254259.4 across 4 years, with a median of -$50471.9 in 2025.
- Annual changes were most pronounced in 2024 — Capital Expenditures soared 167.19% — and 2025, when it sank 164.64%.
- MindWalk Holdings' Capital Expenditures stood at -$220510.7 in 2023, then surged by 78.41% to -$47598.8 in 2024, then fell by 12.07% to -$53345.0 in 2025, then surged by 1173.51% to $572662.2 in 2026.
- Business Quant data shows HYFT's Capital Expenditures at $572662.2 in Q2 2026, -$22337.7 in Q1 2026, and -$53345.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -1.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 572,662.23 |
| Apr 30, 2026 | 572,662.23 |
| Jan 31, 2026 | -22,337.66 |
| Jan 31, 2026 | -22,337.66 |
| Oct 31, 2025 | -53,345.05 |
| Oct 31, 2025 | -53,345.05 |
| Jul 31, 2025 | -205,235.46 |
| Jul 31, 2025 | -205,235.46 |
| Apr 30, 2025 | 870,680.85 |
| Apr 30, 2025 | 870,680.85 |
| Jan 31, 2025 | -78,895.81 |
| Jan 31, 2025 | -78,895.81 |
| Oct 31, 2024 | -47,598.77 |
| Oct 31, 2024 | -47,598.77 |
| Jul 31, 2024 | -192,072.05 |
| Jul 31, 2024 | -192,072.05 |
| Apr 30, 2024 | 1.23 Mn |
| Apr 30, 2024 | 1.23 Mn |
| Jan 31, 2024 | 122,054.04 |
| Jan 31, 2024 | 122,054.04 |